HIRA clarifies screening results of cholesterol-lowering agents

Published: 2008-11-21 07:00:00

Updated: 2008-11-21 07:00:00

The Health Insurance Review and Assessment Service (HIRA) reaffirmed its position over the results of lipid-lowering medicines, saying its assessment was made based on their clinical and cost effectiveness profiles.

The HIRA said that as the cholesterol-lowering effect of atorvastatin 10 mg is...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK